What does this research mean for the field?

The A1 adenosine receptor antagonist BG9719 preserves glomerular filtration rate and enhances diuresis when administered alongside furosemide in patients with congestive heart failure. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study explores how the A1 adenosine receptor antagonist BG9719 affects renal function in patients receiving furosemide and ACE inhibitors.

March 19, 2002Circulation

BG9719 (CVT-124), an A ₁ Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy

View Full Paper

Ask AI

Bookmark

Why the study?

Does BG9719 preserve renal function and improve diuresis in patients with congestive heart failure receiving furosemide?

Key Points

This study explores how the A1 adenosine receptor antagonist BG9719 affects renal function in patients receiving furosemide and ACE inhibitors.
Randomized, double-blind, ascending-dose, crossover study with 63 patients having congestive heart failure.
Patients received placebo or BG9719 with and without furosemide on separate days.
Assessment of renal function, urine output, and electrolyte excretion was conducted.
BG9719 increased urine output and sodium excretion with P<0.05.
When combined with furosemide, BG9719 significantly increased diuresis at 0.75-microg/mL concentration.
BG9719 preserved glomerular filtration rate (GFR) while furosemide alone decreased GFR.

Structured PICO

Does BG9719 preserve renal function and improve diuresis in patients with congestive heart failure receiving furosemide?

Population

63 patients with congestive heart failure on standard therapy, including ACE inhibitors

Intervention

BG9719 (3 ascending doses) alone or added to furosemide

Comparator

Placebo alone or added to furosemide

Outcome

Renal function (glomerular filtration rate, creatinine clearance) and electrolyte and water excretion (urine output, sodium excretion)surrogate

A1 adenosine antagonism with BG9719 preserves renal function while promoting natriuresis in heart failure patients treated with furosemide.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports adjunctive A1 antagonism to preserve GFR during furosemide diuresis in HF; extends mechanistic adenosine data to randomized patients.

Cite This Study

Gottlieb et al. (2002) studied this question.

synapsesocial.com/papers/6a17b4eebee663e365ac7b26 https://doi.org/10.1161/hc1102.105264

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Implication

Supports adjunctive A1 antagonism to preserve GFR during furosemide diuresis in HF; extends mechanistic adenosine data to randomized patients.

BG9719 (CVT-124), an A ₁ Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

BG9719 (CVT-124), an A ₁ Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider